UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS

Journal of cardiology, 2017-04, Vol.69 (4), p.660-665

2017

Link zum Volltext

Verfügbarkeit prüfen

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2012-07, Vol.8 (3), p.336

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: 2-Year Follow-Up of the Randomized TWENTE Trial

Journal of the American College of Cardiology, 2013-06, Vol.61 (24), p.2406-2416

2013

Link zum Volltext

Verfügbarkeit prüfen

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT

International journal of cardiology, 2018-10, Vol.268, p.11-17

2018

Link zum Volltext

Verfügbarkeit prüfen

Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial

Catheterization and cardiovascular interventions, 2013-09, Vol.82 (3), p.396-405

2013

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients

Journal of the American College of Cardiology, 2012-04, Vol.59 (15), p.1350-1361

2012

Link zum Volltext

Verfügbarkeit prüfen

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

Journal of the American Heart Association, 2018-02, Vol.7 (3), p.n/a

2018

Link zum Volltext

Verfügbarkeit prüfen

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial

Journal of the American College of Cardiology, 2012-04, Vol.59 (15), p.1350-1361

2012

Link zum Volltext

Verfügbarkeit prüfen

Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial

Catheterization and cardiovascular interventions, 2015-02, Vol.85 (3), p.E76-E82

2015

Link zum Volltext

Verfügbarkeit prüfen

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2015-03, Vol.10 (11), p.1276

2015

Link zum Volltext

Verfügbarkeit prüfen

Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo

International Journal of Cardiovascular Imaging, 2009-01, Vol.25 (1), p.13-23

2009

Link zum Volltext

Verfügbarkeit prüfen

Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

Catheterization and cardiovascular interventions, 2015-01, Vol.85 (1), p.74-81

2015

Link zum Volltext

Verfügbarkeit prüfen

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the entire-thrombolysis in myocardial infarction (TIMI) 23 trial

Circulation (New York, N.Y.), 2002-04, Vol.105 (14), p.1642-1649

2002

Link zum Volltext

Verfügbarkeit prüfen

TCT-572 Final 5-Year Outcome After Implantation of Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in the Broad Patient Population of the Randomized TWENTE Trial

Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B232-B232

2015

Link zum Volltext

Verfügbarkeit prüfen

TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients

Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B231-B231

2015

Link zum Volltext

Verfügbarkeit prüfen

TCT-593 Gender Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From TWENTE and DUTCH PEERS

Journal of the American College of Cardiology, 2015-10, Vol.66 (15), p.B242-B242

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2014-10, Vol.10 (6), p.664

2014

Link zum Volltext

Verfügbarkeit prüfen

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial

JACC. Cardiovascular interventions, 2018-03, Vol.11 (5), p.462-469

2018

Link zum Volltext

Verfügbarkeit prüfen

TCT-588 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in “All-Comer” Patients

Journal of the American College of Cardiology, 2014-09, Vol.64 (11), p.B171-B171

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and Non-Enrolled TWENTE registry

International journal of cardiology, 2014-10, Vol.176 (3), p.885-890

2014

Link zum Volltext

Verfügbarkeit prüfen

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study

JACC. Cardiovascular interventions, 2018-03, Vol.11 (5), p.448-459

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(34)
Science & Technology
(34)
Cardiac & Cardiovascular Systems
(32)
Cardiovascular System & Cardiology
(32)
Humans
(32)
Female
(31)
Male
(31)
Middle Aged
(29)
Percutaneous Coronary Intervention
(28)
Aged
(27)
Treatment Outcome
(19)
Drug-Eluting Stents
(18)
Cardiology
(15)
Cardiovascular
(15)
Drug-Eluting Stent
(14)
Time Factors
(14)
Heart Attacks
(13)
Stents
(13)
Percutaneous Coronary Intervention - Instrumentation
(12)
Risk Factors
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial

Two-year outcome after treatment of severely calcified lesions with newer-generation drug-eluting stents in acute coronary syndromes: A patient-level pooled analysis from TWENTE and DUTCH PEERS

Comparison of Frequency of Periprocedural Myocardial Infarction in Patients With and Without Diabetes Mellitus to Those With Previously Unknown but Elevated Glycated Hemoglobin Levels (from the TWENTE Trial)

Usefulness and safety of the GuideLiner catheter to enhance intubation and support of guide catheters: insights from the Twente GuideLiner registry

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents: 2-Year Follow-Up of the Randomized TWENTE Trial

High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT

Women treated with second-generation zotarolimus-eluting resolute stents and everolimus-eluting xience V stents: insights from the gender-stratified, randomized, controlled TWENTE trial

A Randomized Controlled Trial in Second-Generation Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in Real-World Patients

Long‐Term Outcome of Consecutive Patients With Previous Coronary Bypass Surgery, Treated With Newer‐Generation Drug‐Eluting Stents

A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial

Three-year clinical outcome after treatment of chronic total occlusions with second-generation drug-eluting stents in the TWENTE trial

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Reproducibility of volumetric intravascular ultrasound radiofrequency-based analysis of coronary plaque composition in vivo

Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting xience V stents in the randomized TWENTE trial: Comparison of 2-year clinical outcome

Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the entire-thrombolysis in myocardial infarction (TIMI) 23 trial

TCT-572 Final 5-Year Outcome After Implantation of Zotarolimus-Eluting Resolute Stents Versus Everolimus-Eluting Xience V Stents in the Broad Patient Population of the Randomized TWENTE Trial

TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients

TCT-593 Gender Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents: A Patient-Level Pooled Analysis From TWENTE and DUTCH PEERS

Clinical outcome following second-generation drug-eluting stent use for off-label versus on-label indications: insights from the two-year outcome of the TWENTE trial

5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial

Clinical Outcome Following Stringent Discontinuation of Dual Antiplatelet Therapy After 12 Months in Real-World Patients Treated With Second-Generation Zotarolimus-Eluting Resolute and Everolimus-Eluting Xience V Stents

TCT-588 2-Year Clinical Outcome of the Randomized, Multicenter DUTCH PEERS (TWENTE II) Trial, Comparing Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Stents and Platinum-Chromium Everolimus-Eluting Promus Element Stents in “All-Comer” Patients

Impact of previous coronary artery bypass surgery on clinical outcome after percutaneous interventions with second generation drug-eluting stents in TWENTE trial and Non-Enrolled TWENTE registry

"Silent" Diabetes and Clinical Outcome After Treatment With Contemporary Drug-Eluting Stents: The BIO-RESORT Silent Diabetes Study

Clinical Events and Patient-Reported Chest Pain in All-Comers Treated With Resolute Integrity and Promus Element Stents: 2-Year Follow-Up of the DUTCH PEERS (DUrable Polymer-Based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity) Randomized Trial (TWENTE II)

Suchergebnisse filtern